SynthesisJournal of cancer research and clinical oncology2014
A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.
Synthesis in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review.The British journal of radiology · 2022Pooled it
- AI-based tumor and organ volumetry predicts early progression after Y-90 radioembolization in liver-dominant metastatic disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Review
- TARE-Induced Pan-Immune Inflammation Value as a Prognostic Biomarker in Liver-Dominant Metastatic Colorectal Cancer.Journal of clinical medicine · 2025Article
- Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational Study.Cardiovascular and interventional radiology · 2025Observational
- Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Radiomics-Based Prediction Model for Outcome of Radioembolization in Metastatic Colorectal Cancer.Cardiovascular and interventional radiology · 2024Article
- Interventional radiological therapies in colorectal hepatic metastases.Frontiers in oncology · 2023Review
- Quantitative and qualitative evaluation of liver metastases with intraprocedural cone beam CT prior to transarterial radioembolization as a predictor of treatment response.Research in diagnostic and interventional imaging · 2022Article
- Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A ReviewOncology (Williston Park, N.Y.) · 2022Article
- Review
- Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy.Radiology case reports · 2020Article
- Comparative dosimetry betweenEuropean journal of nuclear medicine and molecular imaging · 2020Article
- The Role of Liver-Directed Therapy in Metastatic Colorectal Cancer.Current colorectal cancer reports · 2018Review
- Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver.Journal of gastrointestinal oncology · 2017Article
- Decision Making in Interventional Oncology: Intra-arterial Therapies for Metastatic Colorectal Cancer-Y90 and Chemoembolization.Seminars in interventional radiology · 2017Review
- Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.Journal of surgical oncology · 2016Article
- Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?Current treatment options in oncology · 2016Review
- Current status of transarterial radioembolization.World journal of radiology · 2016Review
- Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe management of unresectable, chemorefractory colorectal cancer liver metastases (CRCLM) is a clinical dilemma. Yttrium-90 (Y90) radioembolization is a potentially safe and effective treatment for patients with CRCLM who have failed conventional chemotherapy regimens.
methodsA systematic review of clinical studies before November 2012 was performed to examine the radiological response, overall survival and progression-free survival of patients who underwent Y90 radioembolization of unresectable CRCLM refractory to systemic therapy. The secondary objectives were to evaluate the safety profile of this treatment and identify prognostic factors for overall survival.
resultsTwenty studies comprising 979 patients were examined. Patients had failed a median of 3 lines of chemotherapy (range 2-5). After treatment, the average reported value of patients with complete radiological response, partial response and stable disease was 0% (range 0-6%), 31% (range 0-73%) and 40.5% (range 17-76%), respectively. The median time to intra-hepatic progression was 9 months (range 6-16). The median overall survival was 12 months (range 8.3-36). The overall acute toxicity rate ranged from 11 to 100% (median 40.5 %). Most cases of acute toxicity were mild (Grade I or II) (median 39%; range 7-100%) which resolved without intervention. The number of previous lines of chemotherapy (≥ 3), poor radiological response to treatment, extra-hepatic disease and extensive liver disease (≥ 25%) were the factors most commonly associated with poorer overall survival.
conclusionY90 radioembolization is a safe and effective treatment of CRCLM in the salvage setting and should be more widely utilized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.